This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Lannett Company Past Earnings Performance

Past criteria checks 0/6

Lannett Company's earnings have been declining at an average annual rate of -21.9%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been declining at an average rate of 16.4% per year.

Key information

-21.9%

Earnings growth rate

-20.0%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	-16.4%
Return on equity	n/a
Net Margin	-83.4%
Last Earnings Update	31 Mar 2023

Recent past performance updates

Recent updates

Analysts Just Made A Major Revision To Their Lannett Company, Inc. (NYSE:LCI) Revenue Forecasts

Feb 05

A Look At The Fair Value Of Lannett Company, Inc. (NYSE:LCI)

Nov 05

Is Lannett Company (NYSE:LCI) A Risky Investment?

Jun 20

Lannett down 5.5%, SVC gains 5.7% as S&P 500 makes room for Organon

May 27

Is Lannett Company (NYSE:LCI) A Risky Investment?

Mar 18

Independent Director David Drabik Just Sold A Bunch Of Shares In Lannett Company, Inc. (NYSE:LCI)

Feb 11

Lannett shares slide on 2021 forecast cut, QF2 topline fall

Feb 04

What Type Of Returns Would Lannett Company's(NYSE:LCI) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 15

Is Lannett Company (NYSE:LCI) Using Too Much Debt?

Dec 11

Lannett pays off remaining $42M in outstanding loans

Nov 30

Lannett launches authorized generic of Tirosint

Nov 03

Revenue & Expenses Breakdown
Beta

How Lannett Company makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:LCIN.Q Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 23	311	-259	81	25
31 Dec 22	309	-193	78	24
30 Sep 22	314	-237	79	24
30 Jun 22	341	-232	81	22
31 Mar 22	372	-316	77	22
31 Dec 21	406	-288	77	23
30 Sep 21	454	-379	72	23
30 Jun 21	479	-363	68	24
31 Mar 21	511	-195	65	25
31 Dec 20	543	-205	70	26
30 Sep 20	545	-28	73	28
30 Jun 20	546	-33	79	30
31 Mar 20	542	-31	83	33
31 Dec 19	570	-4	83	35
30 Sep 19	628	3	88	38
30 Jun 19	655	-272	88	39
31 Mar 19	692	-276	81	38
31 Dec 18	694	-274	73	31
30 Sep 18	685	-272	79	32
30 Jun 18	685	29	82	29
31 Mar 18	653	46	78	32
31 Dec 17	644	48	82	38
30 Sep 17	631	42	71	37
30 Jun 17	637	-1	73	42
31 Mar 17	667	-3	79	44
31 Dec 16	665	-23	77	52
30 Sep 16	621	-18	74	51
30 Jun 16	566	45	68	45
31 Mar 16	496	75	59	39
31 Dec 15	432	117	54	32
30 Sep 15	420	148	50	31
30 Jun 15	407	150	45	30
31 Mar 15	388	140	45	30
31 Dec 14	369	126	43	31
30 Sep 14	321	98	42	29
30 Jun 14	274	57	39	28
31 Mar 14	233	37	32	25
31 Dec 13	192	18	28	19
30 Sep 13	162	4	23	17
30 Jun 13	151	13	22	16
31 Mar 13	147	11	22	17
31 Dec 12	138	9	22	14
30 Sep 12	129	7	22	13
30 Jun 12	123	4	20	12

Quality Earnings: LCIN.Q is currently unprofitable.

Growing Profit Margin: LCIN.Q is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: LCIN.Q is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.

Accelerating Growth: Unable to compare LCIN.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LCIN.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.3%).

Return on Equity

High ROE: LCIN.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company listing is no longer active

Lannett Company Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022

Lannett Company, Inc. to Report Q2, 2023 Results on Feb 01, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lannett Company, Inc. Reports Asset Impairment Charges for the First Quarter Ended September 30, 2022; Reiterates Asset Impairment Charges Guidance for the Year 2023

Lannett Company, Inc. to Report Q1, 2023 Results on Nov 02, 2022

Recent updates

Lannett Company, Inc. Files Form 15

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022

Lannett Company, Inc. to Report Q2, 2023 Results on Feb 01, 2023

Lannett announces 1-for-4 reverse stock split

Lannett Company Provides Development Update on Biosimilar Insulin Products

Lannett Company, Inc., Annual General Meeting, Jan 25, 2023

Price target decreased to US$1.00

Insufficient new directors

Lannett gains on patent deal for biosimilar insulin device

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lannett Company, Inc. Reports Asset Impairment Charges for the First Quarter Ended September 30, 2022; Reiterates Asset Impairment Charges Guidance for the Year 2023

Lannett Company, Inc. to Report Q1, 2023 Results on Nov 02, 2022

Lannett Company, Inc. Receives FDA Approval to Manufacture Numbrino® at Seymour Plant

Lannett gets FDA approval to manufacture Numbrino® at Seymour plant

Consensus revenue estimates fall by 16%

Lannett Company, Inc. (NYSE:LCI) Analysts Just Slashed This Year's Estimates

Lannett Company, Inc. Announces Subject Dosing Complete for Pivotal Clinical Trial of Biosimilar Insulin Glargine

Full year 2022 earnings: EPS misses analyst expectations

Lannett Company, Inc. Announces Impairment Charges for the Fourth Quarter Ended June 30, 2022

Lannett GAAP EPS of -$2.30, revenue of $74.19M

Lannett Company, Inc. to Report Q4, 2022 Results on Aug 24, 2022

Insufficient new directors

Lannett Company, Inc. Provides Update on Pivotal Clinical Trial for Biosimilar Insulin Glargine

Lannett Company Receives Notice from the NYSE Accepting the Company's Plan for NYSE's Listed Company Manual

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Lannett Company, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Price target decreased to US$3.00

Lannett Company, Inc. Initiates Pivotal Clinical Trial for Biosimilar Insulin Glargine

Lannett: A Self-Inflicted Crisis

Lannett Company, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Analysts Just Made A Major Revision To Their Lannett Company, Inc. (NYSE:LCI) Revenue Forecasts

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Lannett Company, Inc. to Report Q2, 2022 Results on Feb 03, 2022

Lannett Announces FDA Completes Review of Investigational New Drug Application for Biosimilar Insulin Glargine

Lannett Announces Submission of Investigational New Drug (Ind) Application for Biosimilar Insulin Glargine

Non-Executive Independent Chairman recently bought US$86k worth of stock

First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.17 loss in 1Q 2021)

A Look At The Fair Value Of Lannett Company, Inc. (NYSE:LCI)

Price target decreased to US$5.00

Independent Director recently sold US$81k worth of stock

Independent Director notifies of intention to sell stock

Full year 2021 earnings released: US$9.23 loss per share (vs US$0.86 loss in FY 2020)

Price target increased to US$7.00

Lannett Company, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Insufficient new directors

Lannett Company, Inc. Launches Fluvastatin Sodium ER Tablets

Lannett Company, Inc.(NYSE:LCI) dropped from Russell 2000 Dynamic Index

Is Lannett Company (NYSE:LCI) A Risky Investment?

Lannett Announces FDA Acceptance, as a Priority Original Anda, of the Generic Advair Diskus Filing

Lannett down 5.5%, SVC gains 5.7% as S&P 500 makes room for Organon

Non-Executive Independent Chairman recently bought US$84k worth of stock

Price target decreased to US$5.88

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.43 loss in 3Q 2020)

Lannett Company, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Is Lannett Company (NYSE:LCI) A Risky Investment?

Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance

New 90-day low: US$5.93

Independent Director recently sold US$203k worth of stock

Independent Director David Drabik Just Sold A Bunch Of Shares In Lannett Company, Inc. (NYSE:LCI)

Lannett Company, Inc. Enters into Collaboration and License Agreement and Supply Agreement with Sunshine Lake Pharma Co., Ltd

Lannett Company, Inc. Begins Marketing Chlorpromazine Hydrochloride Tablets

Second quarter 2021 earnings released: US$4.36 loss per share (vs US$0.13 profit in 2Q 2020)

Revenue and earnings beat expectations

Lannett Company, Inc. Revises Guidance for Fiscal Year 2021

Lannett shares slide on 2021 forecast cut, QF2 topline fall

Lannett Company, Inc. to Report Q2, 2021 Results on Feb 03, 2021

New 90-day high: US$7.93

Revenue & Expenses Breakdown
Beta